N
Nitrome Biosciences
Developing drugs against a newly identified class of enzymes
About Nitrome Biosciences
Nitrome Biosciences, Inc. is a preclinical stage platform company focused on developing innovative therapeutics targeting a newly identified class of enzymes. These enzymes play a detrimental role in various age-related and inflammation-dependent diseases. The company's primary objective is to create therapies that can slow or halt the progression of these diseases, with a priority indication for neurodegenerative disorders. Nitrome also aims to expand its proprietary platform to address other conditions such as macular degeneration, fibrosis, and cancer.
Nitrome's approach is rooted in a novel hypothesis about the role of nitration in disease progression. Through rigorous research, the company has identified compounds that inhibit the enzymatic activity responsible for harmful nitration processes. This breakthrough has the potential to transform the treatment landscape for patients with unmet medical needs.
The company operates in the biotechnology sector, primarily serving the pharmaceutical and healthcare industries. Nitrome's business model involves the development and eventual commercialization of its proprietary therapeutics. Revenue generation will likely come from partnerships, licensing agreements, and direct sales of approved drugs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Brisbane, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 64.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2021 | $7M | $190M | Bristol-Myers Squibb | — |
| SERIES A✓Equity / VC | Apr 2020 | $38M | $50M | Sofinnova Partners · Dementia Discovery Fund · Mission Bay Capital · AbbVie | ↗ |
Growth signals
Latest recorded traffic for Nitrome Biosciences is 300 monthly website visits, down 62.5% over the last three months. Nitrome Biosciences's team declined 36.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sofinnova Partners
Dementia Discovery Fund
Mission Bay Capital
AbbVie
Bristol-Myers Squibb
Other known investors3 additional known investors
Buck Institute
Breakthrough 307
MBC Biolabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nitrome Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nitrome Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.